Possibilities for assessing vasculogenic mimicry during the preclinical study of antitumor compounds
A. A. Maslyanikova,
S. I. Starostin,
M. D. Ermolenko,
V. V. Trepel,
M. V. Gulyan, 
M. A. Dodokhova,
I. M. Kotieva
M. A. Dodokhova,
I. M. Kotieva https://doi.org/10.34215/1609-1175-2023-3-27-31
Abstract
The dissemination activity of malignant neoplasms largely determines the prognosis in patients with tumors of various localizations. Tumor growth depends on the intensity of formation of new blood and alternative vessels. Vasculogenic mimicry (VM) differs from the conventional neoangiovasculogenetic process involving vascular endothelium. VM is an alternative type of blood supply independent of endothelial vessels, which refers to the formation of vessels lined with tumor cells. Several methods are currently available for detecting VM in vivo; however, immunohistochemical staining of specific antigens remains the gold standard. The main criteria for diagnosing the VM structure have been identified. The successful development of anticancer therapy requires special attention to the preclinical study of the effect of new antitumor compounds on the VM process. Although the specific mechanisms triggering VM formation remains to be elucidated, the strategy of studying this process at the preclinical stage will contribute to the development of new domestic antitumor and antimetastatic drugs with a multifactorial action.
About the Authors
A. A. Maslyanikova
Rostov State Medical University of the Ministry of Healthсare of the Russian Federation
Russian Federation
Russian Federation
Rostov-on-Don
S. I. Starostin
Rostov State Medical University of the Ministry of Healthсare of the Russian Federation
Russian Federation
Russian Federation
Rostov-on-Don
M. D. Ermolenko
Rostov State Medical University of the Ministry of Healthсare of the Russian Federation
Russian Federation
Russian Federation
Rostov-on-Don
V. V. Trepel
Rostov State Medical University of the Ministry of Healthсare of the Russian Federation
Russian Federation
Russian Federation
Rostov-on-Don
M. V. Gulyan
Rostov State Medical University of the Ministry of Healthсare of the Russian Federation
Russian Federation
Russian Federation
Rostov-on-Don
M. A. Dodokhova
Rostov State Medical University of the Ministry of Healthсare of the Russian Federation
Russian Federation
Russian Federation
Margarita A. Dodokhova, Cand. Sci. (Med.), Associate Professor of the Department of Pathological Physiology
29 Nakhichevansky Lane, Rostov-on-Don, 344022, Russia
tel.: (928) 185-09-01
I. M. Kotieva
Rostov State Medical University of the Ministry of Healthсare of the Russian Federation
Russian Federation
Russian Federation
Rostov-on-Don
References
1. The state of oncological care to the Russian population in 2019. Edited by Karpin AD, Starinsky VV, Shakhzadova AO, Moscow: P.A. Herzen Moscow State Medical Research Institute – branch of the Federal State Budgetary Institution “NMIC of Radiology” of the Ministry of Health of Russia, 2020. 239 p. (In Russ.).
2. Fares J, Fares MY, Khachfe HH, Salhab HA, Fares Y. Molecular principles of metastasis: a hallmark of cancer revisited. Signal Transduction and Targeted Therapy 2020;5(1):28. doi: 10.1038/s41392-020-0134-x
3. Qi S, Deng S, Lian Z, Yu K. Novel Drugs with high efficacy against tumor angiogenesis. International Journal of Molecular Sciences. 2022;23(13):6934. doi: 10.3390/ijms23136934
4. Tang E., Lahmi L., Meillan N., Pietta G., Albert S., Maingon P. Treatment strategy for distant synchronous metastatic head and neck squamous cell carcinoma. Current Oncology Reports, 2019;21(11):102. doi: 10.1007/s11912-019-0856-5
5. Zhou J, Wang L, Peng C, Peng F. Co-targeting tumor angiogenesis and immunosuppressive tumor microenvironment. Frontiers Pharmacology. 2022;13:886198. doi: 10.3389/fphar.2022.886198
6. Zhang X., Zhang J., Zhou H., Fan G., Li Q. Molecular mechanisms and anticancer therapeutic strategies in vasculogenic mimicry. Journal of Cancer. 2019;10(25):6327–40. doi: 10.7150/jca.34171
7. Hendrix MJ, Seftor EA, Seftor RE, Chao JT, Chien DS, Chu YW. Tumor cell vascular mimicry: novel targeting opportunity in melanoma. Pharmacology & Therapeutics 2016;159:83–92. doi: 10.1016/j.pharmthera.2016.01.006
8. Simizu S. Vasculogenic mimicry: A dynamic event of malignancy. Biochimica et Biophysica Acta. 2022;1866(3):130084. doi: 10.1016/j.bbagen.2022.130084
9. Chavoshi H, Poormolaie N, Vahedian V, Kazemzadeh H, Mir A, Nejabati HR, Behroozi J, Isazadeh A, Hajezimian S, Nouri M, Maroufi NF. Vascular mimicry: A potential therapeutic target in breast cancer. Pathology Research and Practice, 2022; 234:153922. doi: 10.1016/j.prp.2022.153922
10. Wei X, Chen Y, Jiang X, Peng M, Liu Y, Mo Y, Ren D, Hua Y, Yu B, Zhou Y, Liao Q, Wang H, Xiang B, Zhou M, Li X, Li G, Li Y, Xiong W, Zeng Z. Mechanisms of vasculogenic mimicry in hypoxic tumor microenvironments. Molecular Cancer, 2021, 4;20(1):7. doi: 10.1186/s12943-020-01288-1
11. Luo Q, Wang J, Zhao W, Peng Z, Liu X, Li B, Zhang H, Shan B, Zhang C, Duan C. Vasculogenic mimicry in carcinogenesis and clinical applications. Journal of Hematology and Oncology. 2020, 14;13(1):19. doi: 10.1186/s13045-020-00858-6
12. Lee AW, Ma BB, Ng WT, Chan AT. Management of Nasopharyngeal Carcinoma: Current Practice and Future Perspective. Journal of Clinical Oncology, 2015;33(29):3356–64. doi: 10.1200/JCO.2015.60.9347
13. Luo Q, Wang J, Zhao W, Peng Z, Liu X, Li B, Zhang H, Shan B, Zhang C, Duan C. Vasculogenic mimicry in carcinogenesis and clinical applications. J Hematol Oncol. 2020;13(1):19. doi: 10.1186/s13045-020-00858-6
14. Folberg R, Maniotis AJ. Vasculogenic mimicry. APMIS. 2004; 112(7–8):508–25. doi: 10.1111/j.1600-0463.2004.apm11207-0810.x
15. Ayala-Dominguez L, Olmedo-Nieva L, Munoz-Bello JO, Contreras-Paredes A, Manzo-Merino J, Martinez-Ramirez I. Mechanisms of vasculogenic mimicry in ovarian cancer. Frontiers in Oncology. 2019;9:998. doi: 10.3389/fonc.2019.00998
16. Liu J, Huang J, Yao WY, Ben QW, Chen D.F, He XY, Li L, Yuan YZ. The origins of vacularization in tumors. Frontiers in BioscienceLandmark. 2012;17(7):2559–65. doi: 10.2741/4071
17. Biagioni A, Andreucci E. Immunohistochemistry for VM Markers. Methods in Molecular Biology. 2022;2514:141–52. doi: 10.1007/978-1-0716-2403-6_14
18. Folberg R, Hendrix MJ, Maniotis AJ. Vasculogenic mimicry and tumor angiogenesis. American Journal of Pathology. 2000;156(2):361–81. doi: 10.1016/S0002-9440(10)64739-6
19. Hao XS, Sun BC, Zhang SW, Zhao XL. Correlation between the expression of collgen IV, VEGF and vasculogenic mimicry. Zhonghua Zhong Liu Za Zhi, 2003;25(6):524–6.
20. Delgado-Bellido D, Serrano-Saenz S, Fernández-Cortés M, Oliver FJ. Vasculogenic mimicry signaling revisited: focus on non-vascular VE-cadherin. Molecular Cancer. 2017;16(1):65. doi: 10.1186/s12943-017-0631-x
21. Seftor EA, Meltzer PS, Kirschmann DA, Pe’er J, Maniotis AJ, Trent JM, Folberg R, Hendrix MJ. Molecular determinants of human uveal melanoma invasion and metastasis. Clinical and Experimental Metastasis. 2002;19(3):233–46. doi: 10.1023/a:1015591624171
22. Breier G, Grosser M, Rezaei M. Endothelial cadherins in cancer. Cell and Tissue Research. 2014;355(3):523–7. doi: 10.1007/s00441-014-1851-7
23. Hendrix MJ, Seftor EA, Meltzer PS, Gardner LM, Hess AR, Kirschmann DA, Schatteman GC, Seftor RE. Expression and functional significance of VE-cadherin in aggressive human melanoma cells: role in vasculogenic mimicry. Proceedings of the National Academy of Sciences. 2001;98(14):8018–23. doi: 10.1073/pnas.131209798
24. Cai H, Liu W, Liu X, Li Z, Feng T, Xue Y, Liu Y. Advances and Prospects of Vasculogenic Mimicry in Glioma: A Potential New Therapeutic Target? OncoTargets and Therapy 2020;13:4473–83. doi: 10.2147/OTT.S247855
25. Ge H, Luo H. Overview of advances in vasculogenic mimicry – a potential target for tumor therapy. Cancer Management and Research 2018;10:2429–37. doi: 10.2147/CMAR.S164675
26. Ruzinova MB, Benezra R. Id proteins in development, cell cycle and cancer. Trends in Cell Biology 2003;13(8):410–8. doi: 10.1016/s0962-8924(03)00147-8
27. Xiang T, Lin YX, Ma W, Zhang HJ, Chen KM, He GP, Zhang X, Xu M, Feng QS, Chen MY, Zeng MS, Zeng YX, Feng L. Vasculogenic mimicry formation in EBV-associated epithelial malignancies. Nature Communications. 2018;9(1):5009. doi: 10.1038/s41467-018-07308-5
28. Dobrokhotova YuE, Borovkova EI, Arutyunyan AM, Danelyan SZh, Malysheva EM, Zharkov NV, Aksenova TN. Features of vasculogenesis and angiogenesis in the placenta during the chemotherapy. Russian Journal of Woman and Child Health. 2021;4(1):23–30 (In Russ.). doi: 10.32364/2618-8430-2021-4-1-23-30
29. Yue WY, Chen ZP. Does vasculogenic mimicry exist in astrocytoma? Journal of Histochemistry and Cytochemistry. 2005; 53(8):997–1002. doi: 10.1369/jhc.4A6521.2005
30. Rotin DL, Titov KS, Kazakov AM. Vasculogenic mimicry in melanoma: molecular mechanisms and clinical significance. Russian Journal of Biotherapy. 2019;18(1):16–24 (In Russ.)
31. García-Quiroz J, García-Becerra R, Santos-Cuevas C, RamírezNava GJ, Morales-Guadarrama G, Cárdenas-Ochoa N, Segovia-Mendoza M, Prado-Garcia H, Ordaz-Rosado D, Avila E, Olmos-Ortiz A, López-Cisneros S, Larrea F, Díaz L. Synergistic antitumorigenic activity of calcitriol with curcumin or resveratrol is mediated by angiogenesis inhibition in triple negative breast cancer xenografts. Cancers (Basel). 2019;11(11):1739. doi: 10.3390/cancers11111739
32. Chen YS, Chen ZP. Vasculogenic mimicry: a novel target for glioma therapy. Chinese Journal of Cancer. 2014;33(2):74–9. doi: 10.5732/cjc.012.10292
33. Wang H, Lin H, Pan J, Mo C, Zhang F, Huang B, Wang Z, Chen X, Zhuang J, Wang D, Qiu S. Vasculogenic mimicry in prostate cancer: the roles of EphA2 and PI3K. Journal of Cancer, 2016;7(9):1114–24. doi: 10.7150/jca.14120
34. Andonegui-Elguera MA, Alfaro-Mora Y, Cáceres-Gutiérrez R, Caro-Sánchez CS, Herrera LA, Díaz-Chávez J. An overview of vasculogenic mimicry in breast cancer. Frontiers in Oncology. 2020;10:220. doi: 10.3389/fonc.2020.00220
Review
For citations:
Maslyanikova A.A., Starostin S.I., Ermolenko M.D., Trepel V.V., Gulyan M.V., Dodokhova M.A., Kotieva I.M. Possibilities for assessing vasculogenic mimicry during the preclinical study of antitumor compounds. Pacific Medical Journal. 2023;(3):27-31. (In Russ.) https://doi.org/10.34215/1609-1175-2023-3-27-31
Views:
342
Email this article 